Nizar M. Tannir

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Table S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S3 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Table S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S1 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S2 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S5 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S6 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Supplementary Figure S4 from CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

  2026-06-17

• Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

  Nature Communications · 2025-11-25 · 5 citations

• Supplementary Data 1 from SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma

  2025-11-25

• Figure S3 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Table S1 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Figure S2 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Figure S1 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Figure S4 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Table S2 from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• Data from Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

  2025-11-03

• 1057 Early targeted biologics are associated with improved clinical outcomes in immune-related myocarditis, myositis, and myasthenia gravis

  Regular and Young Investigator Award Abstracts · 2025-11-01

• 1064 Clinical and prognostic characterization of high-grade neurologic immune-related adverse events in patients with urinary cancers

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling

  Cell Reports Medicine · 2025-10-30 · 3 citations